Biotech, pharmaceutical and medical companies could catch a bit of a tailwind Thursday, after analysts at Evercore ISI initiated positive coverage on 14 stocks in the sector. Three notable calls center around BioMarin Pharmaceutical Inc (BMRN) - Get Report , AbbVie Inc (ABBV) - Get Report and Regeneron Pharmaceuticals Inc (REGN) - Get Report .
- Cramer: Investors Can't Get Enough of Bristol-Myers Despite Latest Drug Setback
Analyst Josh Schimmer initiated coverage of Regeneron with an outperform rating and $605 price target. Based on Wednesday's closing price near $468, the price target implies about 30% from current levels. That's quite a bit of upside, especially considering REGN stock is up more than 25% since the end of April.
Schimmer also has a bullish outlook on BioMarin, which he slapped with an outperform rating and $100 price target. It implies about $17 a share of upside from its current price near $83, a gain of more than 20%.
Finally, Schimmer placed an outperform rating and $95 price target on AbbVie, which most recently closed near $70. The near-$25 per share of potential upside would represent a gain of more than 35%.
Other notable outperform ratings from Schimmer include Shire PLC (SHPG) - Get Report , which received a $196 price target, Ionis Pharmaceuticals Inc (IONS) - Get Report , which received a $65 price target, and GW Pharmaceuticals (GWPH) - Get Report , which received a $154 price target.
More of What's Trending on TheStreet:
- In Trump CEO Council Exodus, Early Movers Stand Out
- Fiat Chrysler Skids as Dongfeng Motor Denies Interest
- These 10 Office Catch-Phrases Will Drive Your Coworkers Absolutely Insane
- This Ex-Domino's Employee Reveals Why He Left to Start a 'Better' Pizza Chain
This article is commentary by an independent contributor. At the time of publication, the author had no positions in the stocks mentioned.